This shareable PDF can be hosted on any platform or network and is fully compliant with publisher copyright.
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
This page is a summary of: Aspirin, NOACs, Warfarin: which is the best choice to tackle cognitive decline in elderly patients? Insights from the GIRAF and ASCEND-Dementia trials presented at the AHA 2021, European Heart Journal - Cardiovascular Pharmacotherapy, November 2021, Oxford University Press (OUP),
DOI: 10.1093/ehjcvp/pvab081.
You can read the full text:
The following have contributed to this page
